ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: At present, tyrosine kinase inhibitors (TKIs) are still one of the main therapies for the treatment of CML, which greatly improves the survival rate of patients with CML by targeting the abnormal BCR-ABL [20].